Amani Therapeutics, Inc.
StreetZero Signal 71
About Amani Therapeutics, Inc.
Amani Therapeutics is a New York-based biotechnology company focused on developing treatments for serious neuropsychiatric disorders, specifically targeting schizophrenia. Its flagship candidate, AM-01, is a fixed-dose combination product that includes clozapine and a Phase 3–ready NCE with worldwide rights in-licensed from AstraZeneca. The company was newly formed and backed by RTW Investments, with a mission to deliver highly efficacious and safer medicines for people living with serious psychiatric illness.
LATEST FUNDINGSeries A
$35.0M
Announced 2026-10-01
TOTAL RAISED$25M
IN THE NEWS
EMPLOYEES—
FOUNDED—
HQNEW YORK, NY
Industry
Other Health Care
Tags
BiotechnologySeries ANeuropsychiatric Disorders
Investors
Key highlights
- Raised $25M Series A in March 2026 to advance AM-01 for schizophrenia.
- In-licensed Phase 3-ready NCE from AstraZeneca for lead program.
- Appointed Rob Swoboda as COO and Carla Canuso, MD, as CMO.
- Newly formed NYC-based company backed by RTW Investments.
- Focuses on safer and more effective treatments for serious psychiatric illness.
Ask StreetZero about Amani Therapeutics, Inc.
Put our AI to work on this deal.
Similar companies
Other Other Health Care deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account